NextCure has set the dates for a contingent-value-right distribution tied to its planned combination with Avere Therapeutics. The rights are designed to give eligible NextCure stockholders a share of any qualifying future proceeds from the company’s pre-merger assets; they are not an immediate cash payment.
-
One right for each eligible share: Holders of NextCure common and preferred stock on December 8, 2026 are expected to receive one contingent value right for each share they hold, subject to exceptions in the merger agreement.
-
Distribution depends on the merger proceeding: The rights are expected to be distributed on December 14, one business day after the anticipated effective time of the first merger step. The distribution will occur only if that step takes effect.
-
What the rights cover: Each right entitles its holder to a share of 90% of gross proceeds, after permitted deductions, if NextCure receives consideration during the rights’ term from a sale, transfer, license or other disposition of rights to develop and commercialize its pre-merger legacy assets.
-
No guaranteed payout: A right pays only if a qualifying transaction generates proceeds during the specified term and the agreement’s conditions are met. The announcement does not set a fixed cash value for the rights.
The distribution separates potential future proceeds from NextCure’s legacy assets from the planned merger with Avere. Eligible stockholders would receive the rights, but their eventual value depends on whether qualifying asset transactions occur and how much they generate.
